October 29, 2019
A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.
October 21, 2014
A New Jersey federal judge overseeing multidistrict litigation over whether Pfizer Inc. conspired to bar competition for its epilepsy treatment Neurontin and promoted off-label uses on Monday appointed a special master to handle a dispute over attorneys' fees between opt-out plaintiff Walgreen Co. and class counsel.
September 15, 2014
Walgreen Co. urged a New Jersey federal court Friday to deny class counsel a cut of the fees from Walgreen's antitrust settlement with Pfizer Inc. over its epilepsy treatment Neurontin, saying class counsel in the multidistrict litigation actively worked against Walgreen after it opted out of the class.
April 21, 2014
Pfizer Inc. on Monday agreed to pay $190 million to settle a class action coursing through New Jersey federal court alleging that the drug giant conspired to bar competition for its epilepsy treatment Neurontin and promoted off-label uses, signaling an end to more than a decade's worth of contentious antitrust litigation.
August 08, 2013
A New Jersey federal judge on Thursday refused Pfizer Inc.'s bid to squash a multidistrict litigation accusing the pharmaceutical giant of conspiring to bar competition for its epilepsy treatment Neurontin and promoting off-label uses, saying there are many factual disputes that must be resolved.
December 03, 2012
A New Jersey federal judge on Friday refused to release documents from patent litigation over Pfizer's Neurontin to a class of plaintiffs accusing it of inhibiting the epilepsy treatment's generic rivals, saying their allegations weren't enough to overcome attorney-client privilege.
July 07, 2011
A magistrate judge refused Tuesday to sanction Pfizer Inc. by striking its denial that it promoted off-label uses of epilepsy drug Neurontin, the latest in a New Jersey multidistrict litigation claiming the drugmaker used patent litigation to delay generic competition.
June 10, 2011
A New Jersey federal judge on Thursday upheld sanctions against Pfizer Inc. for a witness testimony violation in a class action that accuses the pharmaceutical giant of using patent litigation to delay generic competition for epilepsy drug Neurontin.
February 08, 2011
Pfizer Inc. has appealed a magistrate judge's order sanctioning the company for a witness testimony violation in a class action that accuses the pharmaceutical giant of using patent litigation to delay generic competition for epilepsy drug Neurontin.
January 26, 2011
A federal court has sanctioned Pfizer Inc. for a witness testimony violation and also certified a class of direct purchasers that accuses the pharmaceutical giant and a subsidiary of using patent litigation to delay generic competition for epilepsy drug Neurontin.